The main purpose of this study was to estimate possible climate change effects on the annual streamflow of Filyos River (Turkey). Data for annual streamflow and climatic parameters were obtained from streamflow gauging stations on the river and Bartın, Karabük, Zonguldak meteorological observation stations. Time series analysis was performed on 46 years of annual streamflow data and 57 years of annual mean climatic data from three monitoring stations to understand the trends. Pettitt change-point analysis was applied to determine the change time and trend analysis was performed to forecast trends. To reveal the relationship between climatic parameters and streamflow, correlation tests, namely, Spearman's rho and Kendall's tau were applied. The results of Pettitt change-point analysis pointed to 2000 as the change year for streamflow. Change years for temperature and precipitation were detected as 1997 and 2000, respectively. Trend analysis results indicated decreasing trends in the streamflow and precipitation, and increasing trend in temperature. These changes were found statistically significant for streamflow (p < 0.05) and temperature (p < 0.01). Also, a statistically significant (p < 0.05) correlation was found between streamflow and precipitation. In conclusion, decreasing precipitation and increasing temperature as a result of climate change initiated a decrease in the river streamflow.

The aim of the study was to investigate the plasma and muscle pharmacokinetic of enrofloxacin (ENR) and its active metabolite ciprofloxacin (CIP) in Nile tilapia (Oreochromis niloticus) following single intravascular (IV), intraperitoneal (IP), or oral (PO) administration at 30 ± 1 °C. In this study, 234 healthy Nile tilapia (120–150 g) were used. The fish received a single IV, IP, or PO treatment of ENR at a dose of 10 mg/kg. The plasma and muscle tissue concentrations of ENR and CIP were measured using high–performance liquid chromatography with fluorescence detection and were evaluated using non–compartmental analysis. The elimination half–life, volume of distribution at steady state, and total body clearance of ENR were 21.7 h, 2.69 L/kg, and 0.09 L/h/kg, respectively. The peak plasma concentrations of ENR after IP or PO administration were 6.11 and 4.21 µg/mL at 0.25 and 2 h, respectively. The bioavailability of ENR for IP or PO routes was 78% and 86%, respectively. AUC_{(0–120)muscle}/AUC_{(0–120)plasma} ratios following the IV, IP, or PO administrations were 1.43, 1.49, and 1.07, respectively. CIP was detected after all routes, but the AUC_0–last ratios of CIP to ENR were <1.0% for plasma and muscle. ENR was detected up to 120 h following the IV, IP, or PO administrations. The long residence time of ENR after single IV, IP, or PO administration ensured the plasma concentration was ≥1 × MIC for bacteria with threshold MIC values of 0.92, 0.72, and 0.80 μg/mL over the whole 120 h observed. However, further studies are necessary to determine the optimum pharmacokinetic/pharmacodynamics data of ENR for the treatment of infections caused by susceptible bacteria in tilapia.